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Abstract
Introduction: In this study we aimed to validate the prognostic value of DC-SCRIPT mRNA expression in a large
independent breast cancer cohort. In addition, since DC-SCRIPT is a transcriptional co-regulator of nuclear
receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its
predictive value for response to tamoxifen treatment.
Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and
associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS)) using
univariate and multivariable Cox regression analysis. Logistic and Cox regressions were used to associate DC-SCRIPT
levels with clinical benefit and progression-free survival (PFS) for 296 patients treated with first-line systemic
tamoxifen for advanced disease.
Results: In univariate and multivariable analysis higher DC-SCRIPT levels were associated with a favorable outcome
for both the entire cohort and patients with lymph node-negative (LNN) disease that did not receive adjuvant
therapy (DFS, MFS and OS; all, P < 0.001). This association was most pronounced in small (pT1) tumors, in ESR1-
positive tumors and in tumors with low ESR2 expression. For first-line endocrine therapy for advanced disease no
predictive association was seen with clinical benefit or PFS.
Conclusions: This study provides a higher level of evidence that DC-SCRIPT is indeed an independent, pure
prognostic, factor for primary breast cancer and shows that DC-SCRIPT mRNA expression is most informative for
either ESR1-positive and/or ESR2-low pT1 tumors.
Introduction
Estrogens influence the aggressiveness of breast cancer
through their cognate nuclear receptors. In particular,
the estrogen receptor-alpha (ERa) (ESR1) - present in
tumor cells of about 70% to 75% of all breast tumors -
is considered crucial because of its proliferation-
inducing actions and for that reason is an important
target for therapy. Next to ESR1, a second ER exists,
ERb (ESR2). ESR2 counteracts the activity of ESR1 in
many systems [1,2] and is also expressed in the majority
of breast cancers. Apart from breast epithelial tumor
cells, ESR2 is also expressed in adjacent infiltrating lym-
phocytes, fibroblasts, and endothelial cells, all of which
are known to influence tumor growth [3]. However, its
precise role in breast cancer progression is less well
defined.
DC-SCRIPT (zinc finger protein 366 [ZNF366]) is a
recently identified nuclear receptor co-regulator first
identified in immune cells [4-6]. Nuclear receptor co-
regulators are proteins that can activate or repress the
transcriptional activity of nuclear receptors. DC-SCRIPT
is in this respect a unique co-regulator as we have
shown that it enhances the activities of the nuclear reti-
noic acid receptor (RAR) and peroxisome proliferator-
activated receptor (PPAR) heterodimers, RARa/RXRa
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and PPARg/RXRa, but represses the activities of ESR1
and progesterone receptor (PGR) [7]. We also showed
that DC-SCRIPT was an independent prognostic factor,
particularly for hormone receptor-positive breast cancer.
This led us to postulate that the anti-proliferative effect
of DC-SCRIPT in breast cancer cells could be mediated
by simultaneous modulation of the activity of multiple
nuclear receptors.
To provide a higher level of evidence for DC-SCRIPT
mRNA expression as a prognostic marker, we now
report on DC-SCRIPT expression and its significance in
a retrospective validation study of 1,505 breast cancer
patients with known ESR1, ESR2, and PGR expression
levels. The primary objective of this study was to con-
firm the relationship between DC-SCRIPT mRNA levels
measured in primary breast cancers and tumor aggres-
siveness in a much larger, independent, breast cancer
cohort. The main clinical endpoints for assessing the
prognostic value of DC-SCRIPT expression were dis-
ease-free survival (DFS), metastasis-free survival (MFS),
and overall survival (OS) in lymph node-negative (LNN)
patients who had not received adjuvant systemic ther-
apy; this approach allowed us to determine tumor
aggressiveness during the natural course of the disease.
As DC-SCRIPT modulates ER activity, we also analyzed
the prognostic value of DC-SCRIPT separately in tumors
stratified by ESR1 and ESR2 expression. Since several
co-regulators of nuclear receptors also modulate
response to therapy [8,9], we also assessed, as a second-
ary aim of this study, the predictive value of DC-SCRIPT
by using clinical benefit and progression-free survival
(PFS) after first-line tamoxifen for advanced disease as
the main endpoints.
Materials and methods
Patients
The protocol to study biological markers associated with
disease outcome was approved by the medical ethics
committee of the Erasmus Medical Center (Rotterdam,
The Netherlands) (MEC 02.953). This retrospective study
used 1,505 M0 (no metastasis) and 32 M1 (with metasta-
sis) blind-coded freshly frozen primary tumor tissues of
female patients with primary operable breast cancer from
1978 through 2000. The study was performed in accor-
dance with the Code of Conduct of the Federation of
Medical Scientific Societies in The Netherlands [10], and
consent was not required. Wherever possible, the study
has been reported in accordance with the Reporting
Recommendations for Tumor Marker Prognostic Studies
guidelines [11]. The primary breast tumors were from
patients with detailed clinical follow-up as previously
described [12-14]. ER protein status was determined by
routine ligand-binding assays or enzyme immunoassays
[15], and ESR1, ESR2, and PGR mRNA status was
determined by real-time reverse transcriptase-polymerase
chain reaction (RT-PCR) [14,16,17]. Follow-up, tumor
staging, and response to therapy were defined by
standard International Union Against Cancer (Geneva,
Switzerland) classification criteria [18] and applied pre-
viously by Foekens and colleagues [19]. All 1,537 patients
underwent breast-conserving lumpectomy (44%) or mod-
ified mastectomy (56%). Of the 1,505 patients included
for the evaluation of tumor aggressiveness, 462 lymph
node-positive patients (31%) were treated with adjuvant
systemic therapy, 207 patients received hormonal ther-
apy, 233 chemotherapy, and 22 combination therapy.
Disease recurrence occurred in 836 patients, and 703
developed a distant metastasis. The median follow-up
time of patients alive was 90 months (range of 4 to
260 months).
Eight hundred thirty-seven patients had no involved
nodes and did not receive systemic adjuvant therapy. Of
these 837 LNN patients, 383 had a disease relapse, 300
developed a distant metastasis, and 273 died during fol-
low-up.
Of the 703 patients who developed a distant metasta-
sis, 296 ER-positive patients, including the 32 M1
patients, received hormonal therapy as first-line therapy
for advanced disease. Clinical benefit of first-line tamox-
ifen treatment was observed in 185 patients. Median fol-
low-up time for treatment of advanced disease was 38
(4 to 120) months. Two hundred nineteen patients had
died at the end of the follow-up. None of these patients
had received prior adjuvant hormonal therapy, whereas
19% received prior adjuvant chemotherapy. A more
detailed description of the patients and their therapy is
given in the Supplementary materials and methods
(Additional file 1). Patient and tumor characteristics
combined with DC-SCRIPT mRNA expression and clini-
cal outcome are listed in Table 1.
RNA isolation and quantitative RT-PCR
Tissue processing, RNA isolation, cDNA synthesis, and
quantitative RT-PCR were performed as previously
described [16]. Real-time quantitative PCRs were per-
formed in a 25-μL reaction volume in an M×3000P™
Real-Time PCR System (Agilent, Amsterdam, The Neth-
erlands). In addition to an SYBR-based assay to detect a
129-base pair (bp) DC-SCRIPT transcript covering exon
4 to 5 (forward primer: 5’-AAAGTCAAGCATGGAGT-
CATG-3’; reverse primer: 5’-GCTTCTGAGAGAGGT-
CAAAG-3’), a commercially available Taqman Gene
Expression Assay from Applied Biosystems (Nieuwer-
kerk aan den IJssel, The Netherlands) covering exon
3 to 4 and generating a 62-bp product was used
(Hs00403536_m1, RefSeq NM_152625.1). DC-SCRIPT
levels were readily detected with both assays, and data
generated with these assays correlated significantly
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Table 1 Associations of DC-SCRIPT with clinicopathological and biological factors
Characteristic Number of patients Percentagea DC-SCRIPTb (reference-normalized), × 102
All patients 1,505 100% 0.69 0.73
Age, years
≤ 40 192 13% 0.69 0.72
41-55 561 37% 0.70 0.74
56-70 498 33% 0.70 0.77
>70 254 17% 0.64 0.64
P = 0.15c
Menopausal status
Premenopausal 637 42% 0.72 0.74
Postmenopausal 868 58% 0.66 0.70
P = 0.06d
Grade
Poor 818 54% 0.64 0.74
Unknown 452 30% 0.71 0.68
Moderate and good 235 16% 0.80 0.70
P = 0.001e
Tumor size
pT1, ≤ 2 cm 517 34% 0.81 0.84
>2 cm 988 66% 0.63 0.64
P < 0.001d
Lymph nodes involved
No 837 56% 0.69 0.73
Yes 668 44% 0.68 0.75
P = 0.64d
ESR1 mRNA statusf
Positive, ≥0.2 1,176 78% 0.71 0.73
Negative, < 0.2 329 22% 0.61 0.66
P = 0.004c
PGR mRNA statusf
Positive, ≥0.1 949 63% 0.72 0.74
Negative, < 0.1 556 37% 0.61 0.66
P < 0.001c
ESR2 mRNA statusf
Dichotomized high, ≥0.005 741 49% 0.89 0.95
Dichotomized low, < 0.005 742 49% 0.54 0.49
P < 0.001c
Invasive tumor cell contentg
≥70% 719 48% 0.57 0.51
< 70% 786 52% 0.85 0.91
P < 0.001d
Histological type
DCIS + IDC 194 13% 0.82 0.89
ILC 135 9% 0.81 0.94
IDC 810 54% 0.66 0.69
Mucinous 40 3% 0.56 0.65
Medullary 31 2% 0.69 1.18
P = 0.012e
Intrinsic breast cancer subtypeh 308
Normal-like 22 7% 1.43 1.19
ERBB2+ 63 20% 0.75 0.68
Luminal A 76 25% 0.78 0.89
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(Spearman’s rho = 0.87; P < 0.0001). We therefore per-
formed our analyses on the real-time RT-PCR data gen-
erated with the Taqman assay, which is generally
considered to be more specific. Intron-spanning primer
sequences for the three reference genes - that is, hydro-
xymethylbilane synthase (HMBS), hypoxanthine-guanine
phospho-ribosyltransferase (HPRT1), and b-2-microglo-
bulin (B2M) - and for ESR1, ESR2, PGR, and real-time
PCR conditions for these SYBR-based assays were as
described previously [16,17]. Forty rounds of amplifica-
tion were performed, and fluorescent signals of the Taq-
man probe or SYBR green signal were used to generate
cycle threshold (Ct) values from which mRNA expres-
sion levels were calculated. Ct values of HPRT1 and
B2M were adjusted to the higher HMBS Ct values.
Next, the expression levels of DC-SCRIPT were normal-
ized against the average expression levels of the three
reference genes as follows: mRNA target = 2(mean Ct refer-
ence genes - mean Ct target) [16].
Tissue processing
Primary tumor tissue was processed as described pre-
viously [16]. To assess the amount of invasive tumor
cell nuclei relative to the amount of surrounding stro-
mal cells, 5-μm sections were cut for hematoxylin-and-
eosin staining before, during, and after the sections were
cut for RNA isolation. Only specimens with at least 30%
invasive tumor cell nuclei were included in this study.
Data analysis and statistics
The relationship between DC-SCRIPT and patient and
tumor characteristics was investigated with the use of
non-parametric methods (Spearman rank correlations
for continuous variables and Wilcoxon rank-sum for
dichotomized or Kruskal-Wallis test for ordered vari-
ables). To reduce skewness, DC-SCRIPT levels were
transformed with the Box-Cox transformation. DC-
SCRIPT levels were dichotomized with the previously
identified 66.7% high versus 33.3% low cutoff for DC-
SCRIPT [7]. To test for an association with tumor
aggressiveness and the time to progression during first-
line therapy, Cox regression analysis was applied on the
Box-Cox-transformed and dichotomized DC-SCRIPT
mRNA levels. The hazard ratio (HR) and its 95% confi-
dence interval were computed to correlate the expres-
sion levels with DFS, MFS, OS, and PFS, respectively. In
multivariable analysis, Cox proportional hazards models
for DFS, MFS, OS, and PFS were applied to test DC-
SCRIPT levels added to models with traditional factors.
The proportional hazards assumptions were checked
with Schoenfeld residuals. The analyses were stratified if
necessary. The models for DFS, MFS, and OS for LNN
patients who had not received adjuvant systemic therapy
included age, menopausal status, tumor size, grade, and
ESR1 and PGR mRNA levels. Survival curves were
generated with the method of Kaplan and Meier. The
log-rank test was used to test for differences between
survival curves. Logistic regression was used for the
association of DC-SCRIPT with clinical benefit. Compu-
tations were performed with the STATA statistical pack-
age, release 11.0 (STATA Corp., College Station, TX,
USA) and SPSS 15.0 (SPSS Inc., Chicago, IL, USA). All
P values are two-sided, and a P value of less than 0.05
was considered statistically significant.
Results
Associations of DC-SCRIPT with clinicopathological factors
and histological and intrinsic breast cancer subtypes
In analogy with our previous study, DC-SCRIPT mRNA
expression was readily detected by quantitative RT-PCR
in five normal breast tissues taken adjacent from tumor
tissue and five prophylactic breast tissues (median
[interquartile]: 0.063 [0.015] and 0.054 [0.035], respec-
tively), whereas median levels were over 8-fold lower (P
< 0.05) in 1,505 invasive breast tumors (0.0069
[0.0074]). Table 1 shows the median expression levels
and interquartile ranges of DC-SCRIPT transcripts and
relation with patient and tumor characteristics for these
1,505 patients who were evaluable for prognosis. DC-
SCRIPT levels were positively associated with tumor
grade and ESR1, PGR, and ESR2 steroid hormone recep-
tor expression level and negatively associated with inva-
sive epithelial tumor cell content and tumor size. In
addition, ESR2 was more highly expressed in tumors
with a higher percentage of stromal cells (786 tumors
with 30% to 70% invasive epithelial cells), and ESR1 was
Table 1 Associations of DC-SCRIPT with clinicopathological and biological factors (Continued)
Luminal B 65 21% 0.56 0.36
Basal 82 27% 0.48 0.48
P < 0.001e
aOwing to missing cases, numbers do not always add up to 100%. bMedian level and p50 inter-quartile after normalization on the reference gene set. cP for
Spearman rank correlation test. dP for Mann-Whitney U test. eP for Kruskal-Wallis test, including a Wilcoxon-type test for trend when appropriate. fWith
quantitative polymerase chain reaction cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, respectively, and for ESR2 at the median level of 0.005
(mRNA levels relative to reference gene set). gDichotomized at the median level of 70% invasive tumor cells. hIntrinsic breast cancer subtypes assigned from
Affymetrix microarray by hierarchical clustering of 308 lymph-node negative disease patients who did not receive systemic adjuvant treatment. DCIS, ductal
carcinoma in situ; DC-SCRIPT, dendritic cell-specific transcript gene; ERBB2+, HER2neu-positive; ESR, estrogen receptor gene; IDC, infiltrating ductal carcinoma; ILC,
infiltrating lobular carcinoma; PGR, progesterone receptor gene; pT1, small tumor without lymphatic/vascular invasion.
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more highly expressed in tumors with a high percentage
of invasive epithelial cells (719 tumors with at least 70%
invasive epithelial cells) (P < 0.001) (data not shown).
High levels of DC-SCRIPT were found in breast tumors
with a ductal carcinoma in situ (DCIS) component or
infiltrating lobular carcinoma compared with infiltrating
ductal carcinomas (both P <0.01). Of 308 LNN tumors,
intrinsic subtyping data were available [20]. In these
tumors, basal-like tumors had the lowest levels and nor-
mal-like breast tumors expressed significantly higher
levels of DC-SCRIPT compared with the other intrinsic
subtypes (P < 0.001; Figure S1 in Additional file 2).
Furthermore, luminal A tumors expressed higher levels
of DC-SCRIPT and ESR2 but lower levels of ESR1 com-
pared with luminal B tumors (median levels in luminal
A versus luminal B: 0.0078 and 0.056 for DC-SCRIPT
[P = 0.003], 0.0095 and 0.0023 for ESR2 [P < 0.001], and
6.1 and 13.6 for ESR1 [P < 0.001]). This may be
explained at least partly by the fact that, in this cohort
of 308 LNN tumors, the luminal B tumors contained a
higher percentage of invasive epithelial cells (mean ±
standard deviation [SD]: 77% ± 9% for the n = 64 lumi-
nal B tumors versus 67% ± 12% for the n = 71 luminal
A tumors).
DC-SCRIPT and tumor aggressiveness in univariate and
multivariable analyses
In the analyses including all 1,505 M0 patients, increasing
levels of DC-SCRIPT mRNA were significantly associated
with favorable DFS, MFS, and OS (HR 0.78, 0.74, and 0.77,
respectively; all P < 0.001). To test for a relation between
DC-SCRIPT mRNA levels and tumor aggressiveness (that
is, the natural course of the disease without the confound-
ing effect of systemic adjuvant therapy), we restricted our
next analyses of MFS to those 837 LNN disease patients
who had not received (neo)adjuvant systemic therapy. The
significant relationships of DC-SCRIPT as a continuous
variable in these univariate analyses justified the use of the
previously identified cut point that dichotomized the
cohort in 33.3% of the patients with low levels and 66.7%
of patients with high levels of DC-SCRIPT mRNA in their
primary tumors [7]. In univariate analysis, high levels of
DC-SCRIPT were significantly associated with a favorable
prognosis (HR 0.55; P < 0.001) (Table 2). When added to a
multivariable base model for LNN disease - which included
the traditional prognostic factors of age, menopausal status,
grade, and PGR - stratified by ESR1 and tumor size to meet
the proportional hazards assumption, the association of
DC-SCRIPT with MFS remained highly significant (HR
0.60; P <0.001) (Table 2). Adding ESR2 to the model did
not significantly affect the prognostic value of DC-SCRIPT
in these analyses (Table 2).
Because the proportional hazards assumptions were
violated by ESR1 and tumor size and because DC-
SCRIPT is a transcriptional co-regulator of nuclear
receptors - including the, for breast cancer biologically
relevant, steroid hormone receptors - we next explored
its prognostic value as continuous variable in subgroups
of tumors stratified by steroid hormone receptor status
and tumor size (Table 3 and Figure 1). Subdividing the
837 primary LNN tumors into ESR1-positive and
-negative [14] showed that increasing levels of DC-
SCRIPT were, in univariate and multivariable analyses,
associated with good prognosis only for the patients
with ESR1-positive tumors. Subdividing these LNN
tumors at the median level of ESR2 into high and low
revealed that, in contrast to ESR1, increasing levels of
DC-SCRIPT were, in both univariate and multivariable
analyses, associated with good prognosis only for
patients with primary tumors with low levels of ESR2.
With respect to tumor size, in univariate and multivari-
able analyses, increasing levels of DC-SCRIPT were asso-
ciated with good prognosis only for pT1 (small tumor
without lymphatic/vascular invasion) tumors and not for
larger tumors. These and additional exploratory Cox
univariate analyses are summarized in Table 3. The
prognostic value of DC-SCRIPT is visualized in Kaplan-
Meier curves (Figure 1) as a dichotomized variable in
these biologically relevant LNN ESR1-negative (Figure
1a) and -positive (Figure 1b) and LNN ESR2-high (Fig-
ure 1d) and -low (Figure 1e) subsets in combination
with patients with pT1 primary tumors (Figure 1c, f).
DC-SCRIPT and response to first-line endocrine therapy
DC-SCRIPT expression levels were evaluated in 296 hor-
mone-naïve ER-positive primary breast tumors from
patients whose relapse was treated with first-line tamox-
ifen monotherapy. These patients had not received (neo)
adjuvant endocrine systemic treatment. In univariate
analyses, no statistically significant associations were
observed between DC-SCRIPT as transformed continu-
ous variable and PFS or clinical benefit after start of
first-line treatment with tamoxifen (HR = 1.08 [0.99 to
1.18], P = 0.07 and odds ratio = 0.88 [0.74 to 1.05], P =
0.16, respectively).
Discussion
DC-SCRIPT has been identified as a key modulator of
nuclear receptor activity that has prognostic value in
breast cancer [7]. The clinical conclusions about
DC-SCRIPT mRNA expression as a prognostic marker
in breast cancer were based on non-randomized retro-
spective analyses in three small, breast cancer cohorts
from Nijmegen (The Netherlands) and still required
independent validation. In this study, we provide a
higher level of evidence as we confirm that mRNA
expression values of DC-SCRIPT indicate outcome in an
independent retrospective cohort of 1,505 primary
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breast cancers from Rotterdam. In addition, we confirm
that DC-SCRIPT mRNA expression is a pure prognostic
marker as it indicates - independently of current clinical
prognostic markers such as age, menopausal status,
grade, tumor size, and receptor status - the occurrence
of distant metastasis in patients who did not receive any
adjuvant systemic treatment. Because we used mRNA
extracted from tumor tissue and a different mRNA iso-
lation method (RNA-B versus column-based), an inde-
pendent real-time PCR assay to detect DC-SCRIPT, a
different type of machine to amplify the transcript, and
personnel from another institute, we consider DC-
SCRIPT a robust prognostic marker for patients with
early breast cancer. The patients described in this
Table 2 Univariate and multivariable analyses for metastasis-free survival as a function of DC-SCRIPT in lymph node-
negative disease
Univariate analysis Multivariate analysisa
Factor Number HR 95% CI P value HR 95% CI P value
837
Age, years
≤ 40 114 1 1
41-55 295 0.88 0.63 1.22 0.95 0.67 1.35
56-70 270 0.72 0.51 1.02 0.69 0.40 1.20
>70 158 0.53 0.35 0.81 < 0.01 0.49 0.27 0.90 0.077
Menopausal status
Premenopausal 350 1 1
Postmenopausal 487 0.78 0.62 0.97 0.028 1.08 0.70 1.66 0.731
Grade
Poor 422 1 1
Unknown 262 1.02 0.79 1.30 1.12 0.87 1.44
Moderate and good 153 0.49 0.34 0.71 < 0.001 0.54 0.37 0.78 < 0.001
PGR mRNA statusb
Negative, < 0.1 312 1 1
Positive, ≥0.1 525 0.68 0.54 0.85 0.001 0.71 0.53 0.95 0.022
Tumor size
≤ 2 cm 378 1
>2 cm + unknown 459 1.26 1.00 1.59 0.047 Analyses stratified by tumor size to meet the proportional hazards
assumption
ESR1 mRNA statusb
Negative, < 0.2 199 1
Positive, ≥0.2 638 0.77 0.59 0.99 0.040
Factor analyzed Additions to the base model
DC-SCRIPT
Continuous 837 0.77 0.67 0.88 < 0.001 0.80 0.70 0.92 0.001
33.3% low 277 1 1
66.7% high 560 0.55 0.43 0.69 < 0.001 0.60 0.47 0.76 < 0.001
ESR2 mRNA statusb
Continuous 820 0.88 0.79 0.99 0.034 0.86 0.76 0.96 0.011
Dichotomized low, < 0.005 410 1 1.00
Dichotomized high, ≥0.005 410 0.80 0.63 1.00 0.052 0.75 0.59 0.94 0.014
DC-SCRIPT and ESR2 combined
Both low 183 1 1
DC-SCRIPT low, ESR2 high 91 0.74 0.51 1.08 0.71 0.49 1.04
DC-SCRIPT high, ESR2 low 227 0.49 0.36 0.67 0.55 0.40 0.76
Both high 319 0.50 0.38 0.67 < 0.001 0.52 0.39 0.69 < 0.001
aMultivariable analyses were conducted in two blocks. First, a model including all established clinicopathological factors was fitted. The Cox proportional hazards
assumptions were checked and the analyses were stratified by tumor size and ESR1 to meet the proportional hazards assumption. In a second block, the
contributions of DC-SCRIPT and ESR2 (as continuous or dichotomized variables) were investigated. bWith quantitative polymerase chain reaction cut point for
positive versus negative ESR1 and PGR, 0.2 and 0.1, respectively, and for ESR2 at the median level of 0.005 (mRNA levels relative to reference gene set). CI,
confidence interval; DC-SCRIPT, dendritic cell-specific transcript gene; ESR, estrogen receptor gene; HR, hazard ratio; PGR, progesterone receptor gene; pT1, small
tumor without lymphatic/vascular invasion.
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retrospective study entered the clinic during 1978 to
2000. During this period, adjuvant therapy was not as
widespread as it is nowadays; this circumstance was at
the same time the strength of our cohort for the evalua-
tion of a prognostic marker. The data that emerged
from this study thus validate the hypothesis that DC-
SCRIPT is associated with good prognosis in early dis-
ease and support the idea that DC-SCRIPT acts as a
tumor suppressor in breast cancer progression [7].
Because of the size of this cohort and the biological
function of DC-SCRIPT as a nuclear receptor co-regula-
tor, we were able to include additional subgroup ana-
lyses to extend our insights into the clinical behavior
and relevance of measuring DC-SCRIPT in primary
breast cancers. High levels of DC-SCRIPT mRNA in pri-
mary tumors of breast cancer patients were significantly
related with tumor characteristics that are associated
with good prognosis, such as DCIS, infiltrating lobular
carcinoma, breast tumors of the normal-like and luminal
A subtype, and small (pT1), well-differentiated, steroid
hormone receptor-positive tumors. While ESR1 is loca-
lized mainly in tumors with at least 70% invasive epithe-
lial cells (P < 0.001), we showed for both ESR2 and
DC-SCRIPT a positive correlation with tumors with less
than 70% invasive epithelial cells (P < 0.001). As normal
epithelial cells in tumors with less than 70% invasive
epithelial cells express the highest levels of DC-SCRIPT,
they could be responsible for this correlation. Further-
more, infiltrating leukocytes in the stroma might have
contributed to the detected signal [4,5]. Alternatively, or
additionally, stromal cells may have played a role in the
induction of DC-SCRIPT in the epithelial tumor cells. In
analogy, ESR2 is - apart from breast cancer epithelial
tumor cells - also expressed in adjacent infiltrating lym-
phocytes, fibroblasts, and endothelial cells [3].
Interestingly, in tumors that express relatively high
ESR2 mRNA levels and that in general have a higher
stromal content, DC-SCRIPT expression has little or no
prognostic value. Thus, while in early ESR1-positive
breast cancer DC-SCRIPT inhibits progression of breast
cancer, this effect appears to be neutralized in tumors
high in ESR2. Indeed, ESR2 has been reported to be
dominant over ESR1 and able to counteract the prolif-
eration-inducing activities of ESR1 [1,2]. Unraveling the
precise role of DC-SCRIPT in the complex genomic and
non-genomic interplay between ESR1, ESR2, and their
isoforms [21-23] might turn out to be rewarding for elu-
cidating the ‘yin-yang’ role of these factors in breast
cancer.
As DC-SCRIPT can inhibit ERa and PR activity, a sec-
ond aim of the study was to address whether DC-
SCRIPT affects the response to endocrine therapy. In
our previous study, we had already explored the value of
DC-SCRIPT mRNA expression to indicate outcome in a
cohort of breast cancer patients who received adjuvant
tamoxifen [7]. However, in the adjuvant setting - that,
for ethical reasons, nowadays includes only non-ran-
domly assigned patients among treated and untreated
Table 3 Disease-free survival, metastasis-free survival, and overall survival as a function of continuous DC-SCRIPT in
lymph node-negative disease
Association with continuous DC-SCRIPT Disease-free survival Metastasis-free survival Overall survival
Cohort Number HR 95% CI P value HR 95% CI P value HR 95% CI P value
Lymph node-negative 837 0.82 0.73 0.93 0.001 0.77 0.67 0.88 < 0.001 0.82 0.72 0.94 0.005
ESR1 mRNA-negativea 199 0.94 0.76 1.17 0.59 0.93 0.73 1.18 0.53 0.88 0.70 1.11 0.30
ESR1 mRNA-positivea 638 0.79 0.68 0.90 0.001 0.72 0.62 0.85 < 0.001 0.81 0.69 0.96 0.014
PGR mRNA-negativea 312 0.88 0.74 1.06 0.19 0.84 0.69 1.03 0.10 0.88 0.72 1.08 0.22
PGR mRNA-positivea 525 0.81 0.69 0.94 0.007 0.75 0.63 0.89 0.001 0.82 0.68 0.99 0.04
ESR2 mRNA-lowa 410 0.76 0.64 0.91 0.003 0.69 0.56 0.84 < 0.001 0.73 0.64 0.97 0.026
ESR2 mRNA-higha 410 0.93 0.78 1.11 0.43 0.89 0.73 1.09 0.26 0.92 0.75 1.13 0.41
Tumor size ≤ 2 cm (pT1)b 378 0.74 0.61 0.89 0.001 0.67 0.54 0.83 0.000 0.73 0.59 0.91 0.005
Tumor size >2 cmb 459 0.92 0.79 1.08 0.31 0.86 0.72 1.03 0.10 0.91 0.76 1.09 0.31
ESR1 mRNA-positive, tumor size ≤ 2 cm 306 0.69 0.56 0.85 0.001 0.61 0.48 0.78 < 0.001 0.72 0.56 0.93 0.010
ESR1 mRNA-positive, tumor size >2 cm 332 0.91 0.75 1.10 0.34 0.84 0.68 1.05 0.13 0.90 0.72 1.14 0.39
ESR2 mRNA-low, tumor size ≤ 2 cm 175 0.57 0.43 0.76 < 0.001 0.51 0.37 0.70 < 0.001 0.60 0.44 0.83 0.002
ESR2 mRNA-high, tumor size >2 cm 218 0.98 0.78 1.23 0.84 0.91 0.71 1.18 0.49 0.93 0.74 1.21 0.58
ESR1-positive and ESR2-low, tumor size ≤ 2 cm 147 0.63 0.45 0.87 0.005 0.54 0.38 0.78 < 0.001 0.63 0.43 0.92 0.017
ESR1-positive and ESR2-low, tumor size >2 cm 181 0.94 0.71 1.24 0.66 0.94 0.68 1.29 0.69 1.03 0.73 1.45 0.89
ESR1-positive or ESR2-low or both, tumor size ≤ 2 cm 334 0.65 0.53 0.79 < 0.001 0.57 0.46 0.71 < 0.001 0.67 0.53 0.84 0.001
ESR1-positive or ESR2-low or both, tumor size >2 cm 386 0.90 0.76 1.08 0.25 0.81 0.66 0.99 0.037 0.87 0.71 1.07 0.20
aWith quantitative polymerase chain reaction cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, respectively, and for ESR2 at the median level of
0.005 (mRNA levels relative to reference gene set). bInteraction with continuous DC-SCRIPT (P < 0.05). CI, confidence interval; DC-SCRIPT, dendritic cell-specific
transcript gene; ESR, estrogen receptor gene; HR, hazard ratio; PGR, progesterone receptor gene; pT1, small tumor without lymphatic/vascular invasion.
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arms - one cannot discriminate between tumor aggres-
siveness and response to treatment [24]. The current
retrospective study included hormone-naïve patients
(that is, not having received any [neo]adjuvant endocrine
treatment) who received first-line tamoxifen treatment
for their advanced disease and therefore was better sui-
ted to study a putative relation of DC-SCRIPT and
response to therapy. Despite the positive association of
DC-SCRIPT with ESR1, DC-SCRIPT levels were unable
to identify patients with ESR1-positive primary tumors
at high or low risk to progress if treated with tamoxifen.
Thus, although DC-SCRIPT can modulate the activity of
ESR1, it does not affect the response to endocrine
therapy with tamoxifen in advanced breast cancer. The
early loss of DC-SCRIPT during cancer progression
might explain this absence of a response in the meta-
static disease setting.
Conclusions
This independent retrospective quantitative RT-PCR
study validates that high levels of DC-SCRIPT are asso-
ciated with reduced tumor aggressiveness. The associa-
tion is particularly strong for small tumors with high
ESR1 or low ESR2 mRNA levels or both. Finally,
although DC-SCRIPT negatively regulates ESR1 and
PGR activity, DC-SCRIPT levels measured in the
Figure 1 Metastasis-free survival as a function of dichotomized DC-SCRIPT. Metastasis-free survival is shown as a function of dichotomized
DC-SCRIPT in 837 lymph-node negative, primary breast cancer patients after subdividing them according high and low ESR1 and ESR2 in the
primary tumor and tumor size. (a) ESR1 negative primary breast tumors, (b) ESR1 positive primary breast tumors, (c) ESR1 positive pT1 primary
breast tumors, (d) ESR2 low primary breast tumors, (e) ESR2 high primary breast tumors, (f) ESR2 low pT1 primary breast tumors. Quantitative
polymerase chain reaction cut points are shown for high versus low DC-SCRIPT (66.7% versus 33.3%) [7], for positive versus negative ESR1 (0.2)
[14], and for ESR2-low versus -high at the median level of 0.005 (mRNA levels relative to reference gene set). Patients at risk are indicated. DC-
SCRIPT, dendritic cell-specific transcript; ESR, estrogen receptor; pT1, small tumor without lymphatic/vascular invasion.
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primary tumors are not associated with response to
first-line endocrine treatment for advanced disease. This
finding is in line with DC-SCRIPT as an early marker
for disease.
Additional material
Additional file 1: Supplementary materials and methods. A word file
containing additional Materials and methods [25-28].
Additional file 2: Figure S1 - DC-SCRIPT mRNA expression in breast
cancer subtypes. The box-plot shows the five statistics (lower whisker is
5% minimum, lower box part is 25th percentile, solid line in box presents
the median, upper box part is 75th percentile and upper whisker is 95%
maximum). Figure depicts P for Mann-Whitney U test to identify
significantly different expression of DC-SCRIPT in between subtypes.
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